When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
SURF - Trillium Therapeutics: A Potentially Undervalued CD47 Player
Surface Oncology Inc.
Trillium Therapeutics has two lead candidates that encourage immune cells known as “macrophages” to gobble up cancer cells by blocking a protein known as CD47.
However, the CD47 inhibitor space is incredibly crowded. There are 10+ groups developing a drug that hits the CD47 pathway.
Even with the run up over the past year, Trillium’s pipeline is valued at the low end of what has been paid for other CD47 inhibitors.